Diamond Biotechnology Co., Ltd (6815) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Diamond Biotechnology Co., Ltd TWD 3.72, price TWD 23.85, upside -84.4%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Diamond Biotechnology Co., Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Diamond Biotechnology Co., Ltd researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. The company offers skin care products under the Timera and Diamond Beauty brands. It also leases medical equipment. Diamond Biotechnology Co., Ltd was founded in 2014 and is based in Taipei, Taiwan.
Stock analysis
Diamond Biotechnology Co., Ltd (6815) currently trades at 23.85 TWD, while our model-based Fair Value estimate is 3.72 TWD, implying the stock looks roughly 541.8% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 2.45 TWD (bear) to 4.64 TWD (bull), the price of 23.85 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Diamond Biotechnology Co., Ltd reported revenue of 501M TWD in FY2025 versus 395M TWD in FY2021, a compound +6.1%/yr. Reported net income was −70.3M TWD in FY2025.
Key figures
Market cap 1.1B TWD (≈ $35.9M) · P/S ratio 2.28 · EPS (TTM) −1.78 TWD · Net margin −14.0% · Return on equity −12.1% · Return on assets (EBIT) 5.3% · Operating margin −54.1% · Revenue (TTM) 501M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 68% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −84%, 6815 screens richer than that median.
Fair Value models
Bear 2.45 TWDFair Value 3.72 TWDBull 4.64 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.30/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−34.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.9% (2020) → −14.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Diamond Biotechnology Co., Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−84% · Bottom 25%
Profitability
Return on assets−6% · Below median
Net margin (TTM)−14% · Below median
Operating margin (TTM)−54% · Bottom 25%
Growth and dividend
Revenue growth−52% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.32× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B0.07× · Cheapest 25%
P/S (TTM)0.07× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)0· sector 31
PAST (return on equity)0· sector 7
HEALTH (low debt)84· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Diamond Biotechnology Co., Ltd (6815) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3.72 TWD versus a price of 23.85 TWD, about −84% upside (overvalued).
What is the fair value of 6815?
Our model-based fair value for Diamond Biotechnology Co., Ltd is 3.72 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 23.85 TWD.
What is the quality score of 6815?
Diamond Biotechnology Co., Ltd has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diamond Biotechnology Co., Ltd (6815)?
Our model-based price target is the fair value of 3.72 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 2.45 TWD, optimistic scenario 4.64 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Diamond Biotechnology Co., Ltd stock forecast for 2026?
Our models put fair value at 3.72 TWD, about −84% upside versus a price of 23.85 TWD (overvalued). Cautious scenario 2.45 TWD, optimistic scenario 4.64 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Diamond Biotechnology Co., Ltd (6815)?
Diamond Biotechnology Co., Ltd reported trailing-twelve-month revenue of about 501M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Diamond Biotechnology Co., Ltd (6815)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diamond Biotechnology Co., Ltd it is 3.72 TWD per share (as of Sep 24, 2026), against a price of 23.85 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Diamond Biotechnology Co., Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6815 trades above its calculated fair value: price 23.85 TWD, fair value 3.72 TWD, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6815?
No. The price is what the market pays today (23.85 TWD); the fair value is what the company's own numbers justify (3.72 TWD). For Diamond Biotechnology Co., Ltd the two are 20.14 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Diamond Biotechnology Co., Ltd worth?
The market values Diamond Biotechnology Co., Ltd at about 1.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 23.85 TWD; our models calculate a fair value of 3.72 TWD per share.
What do the bullish and bearish scenarios say about 6815?
Our models span a range for Diamond Biotechnology Co., Ltd: cautious scenario 2.45 TWD, base 3.72 TWD, optimistic 4.64 TWD per share (as of Sep 24, 2026, price 23.85 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Diamond Biotechnology Co., Ltd (6815)?
Balance-sheet figures for Diamond Biotechnology Co., Ltd (as of Sep 24, 2026): return on equity −12.1%, debt of 0.32 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is 6815 from its 52-week high?
Diamond Biotechnology Co., Ltd trades at 23.85 TWD, about 68% below its 52-week high of 74.50 TWD and 6% above the low of 22.50 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 3.72 TWD is for.
Which stocks are comparable to Diamond Biotechnology Co., Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diamond Biotechnology Co., Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 23.85 TWD, calculated fair value 3.72 TWD (−84%), Quality Score 23/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6815 calculated?
We run Diamond Biotechnology Co., Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.72 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Diamond Biotechnology Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Diamond Biotechnology Co., Ltd (6815)?
The closing price on Sep 24, 2026 was 23.85 TWD. Our model-based fair value is 3.72 TWD, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Diamond Biotechnology Co., Ltd right now?
The price sits above even our optimistic bull case (4.64 TWD). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.45 TWD to 4.64 TWD) leaves room in how you read the outcome.
Key figures of Diamond Biotechnology Co., Ltd
How large is the market capitalisation of Diamond Biotechnology Co., Ltd (6815)?
The market capitalisation of Diamond Biotechnology Co., Ltd is 1.1B TWD (≈ $35.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Diamond Biotechnology Co., Ltd (6815)?
The price-to-sales ratio of Diamond Biotechnology Co., Ltd is 2.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Diamond Biotechnology Co., Ltd (6815)?
Earnings per share at Diamond Biotechnology Co., Ltd are −1.78 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Diamond Biotechnology Co., Ltd (6815)?
The net margin of Diamond Biotechnology Co., Ltd is −14.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Diamond Biotechnology Co., Ltd (6815)?
The return on equity (ROE) of Diamond Biotechnology Co., Ltd is −12.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diamond Biotechnology Co., Ltd (6815)?
On an EBIT basis the return on assets of Diamond Biotechnology Co., Ltd is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diamond Biotechnology Co., Ltd (6815)?
The operating margin of Diamond Biotechnology Co., Ltd is −54.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diamond Biotechnology Co., Ltd (6815)?
Revenue at Diamond Biotechnology Co., Ltd is growing −51.7% versus a year earlier (3y avg +4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Diamond Biotechnology Co., Ltd (6815)?
Earnings per share at Diamond Biotechnology Co., Ltd are growing −81.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Diamond Biotechnology Co., Ltd (6815) generate?
The free cash flow of Diamond Biotechnology Co., Ltd is −3.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Diamond Biotechnology Co., Ltd (6815) carry?
The net debt of Diamond Biotechnology Co., Ltd is 83.2M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Diamond Biotechnology Co., Ltd in the live analysis
One click puts Diamond Biotechnology Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
